Clinical trials: Healthy Subjects in Fasted and Fed State
Healthy Volunteers in Fed and Fasted State
Pharmacokinetics of Zelquistinel in Fasted or Fed State
The primary purpose of this study is to assess the effect of food on the rate and extent of absorption of a single dose of Zelquistinel 3 mg or 10 mg oral tablets tablets in healthy adult volunteers.
- Trial name
- GATE-251 (NCT07099989)
- Testing
- Zelquistinel 3 mg, Zelquistinel 10 mg
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Syndeio Biosciences, Inc
Healthy Volunteers in Fed and Fasted State
Fed-Fast Crossover Study to Assess the Effect of Food With CTx-1301 in Healthy Subjects
The primary purpose of this study is to assess the effect of food on the rate and extent of absorption and the overall bioavailability of a single dose of CTx-1301 25 mg trimodal tablets in healthy adult volunteers.
- Trial name
- Fed-Fast (NCT04449250)
- Testing
- Dexmethylphenidate
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Cingulate Therapeutics
Healthy Subjects in Fasted and Fed State
The Purpose of the Study is to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR in Healthy Subjects Under Fasting and Fed Conditions
This is a bioequivalence study of two doses of the dapagliflozin/metformin XR tablet manufactured at two different plants.
- Trial name
- NCT03216278
- Testing
- Dapagliflozin/metformin XR 5/500mg, Dapagliflozin/metformin XR 5/500 mg, Dapagliflozin/metformin XR 10/1000mg
- Where
- Brazil
- Volunteers
- 284 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Subjects
A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961
This open label study will evaluate the pharmacokinetics (PK) following single oral doses of different formulations of PF-06882961, including controlled release (CR) tablets at 2 release rates (long and short duration), an…
- Trial name
- NCT03492697
- Testing
- PF-06882961 Immediate Release Tablet, PF-06882961 Controlled Release Tablet (long), PF-06882961 Controlled Release Tablet (short)
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)
To demonstrate bioequivalence of a 2.5 mg saxagliptin/500 mg metformin (glucophage) immediate release (IR) fixed dose combination (FDC) tablet to the 2.5 mg saxagliptin tablet and 500 mg metformin IR tablet co-administered to…
- Trial name
- NCT00899470
- Testing
- Co-administration of Saxagliptin and Metformin IR, Fasted, Saxagliptin/Metformin, Fasting, Co-administration of Saxagliptin and Metformin IR, Fed
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
GXR RM (Glucophage® Extended Release Reduced Mass) 500 Milligram (mg) Korea Bioequivalence (BE) Study
The purpose of this study was to assess bioequivalence (BE) of newly developed Glucophage® XR (GXR) reduced mass (RM) tablet (metformin hydrochloride 500 milligrams (mg) test tablet) and marketed Glucophage ® XR tablet (metformin…
- Trial name
- NCT04684420
- Testing
- Glucophage® XR RM Test, Glucophage® XR Reference
- Where
- South Korea
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Healthy Volunteer
Bioequivalence and Food Effect Bioavailability Study of Lumacaftor Film-Coated Tablets
The objective of this study is to assess bioequivalence of lumacaftor from Lumacaftor 200 mg Film-Coated Tablet Formulation (Qanatpharma) versus the reference commercial product, Lumacaftor 200 mg /Ivacaftor 125 mg Combination…
- Trial name
- NCT05968612
- Testing
- Lumacaftor 200 mg/Ivacaftor 125 mg Film-Coated Tablet, Lumacaftor 200 mg Film-Coated Tablet Formulation
- Where
- Canada
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Qanatpharma Canada LTD
Healthy
Safety and Pharmacokinetics Study of a New Drug for Type 2 Diabetes
The purpose of this study is to determine the toxicity, tolerability and safety of single ascending doses of GMC-252-L-Lysine Salt in healthy male subjects.
- Trial name
- NCT02686281
- Testing
- GMC-252-L-Lysine
- Where
- United Kingdom
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Genmedica Therapeutics S.L.
Healthy Volunteers
Study to Compare the Pharmacokinetics, Safety and Tolerability of the Pediatric and Adult Branaplam Formulation in Healthy Adults and the Effect of Food on the Latter.
This is a Phase 1 study designed to assess the relative bioavailability (BA), safety and tolerability and PK of the pediatric and adult formulations of branaplam.
- Trial name
- NCT05330286
- Testing
- LMI070
- Where
- United Kingdom
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Adrenal Insufficiency
A Study of Infacort® Versus Cortef® in Healthy Adult Male and Female Subjects
This was a two-part, single centre, open-label, randomised, single dose, two-period, crossover study to evaluate the bioavailability of Infacort® versus Cortef® immediate release hydrocortisone tablets in dexamethasone-suppressed…
- Trial name
- NCT03311932
- Testing
- Infacort®, Cortef®
- Where
- United Kingdom
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Neurocrine UK Limited
Healthy
Assessment of Relative Bioavailability of NKTR-118 in Three Formulations in Healthy Subjects
The is an assessment of Relative Bioavailability of NKTR-118 in Three Formulations in Healthy Subjects.
- Trial name
- NCT01365000
- Testing
- NKTR118 Formulation 1, NKTR118 Formulation 2, NKTR118 Formulation 3
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Pain
A Study of Whether 2 New Oral Formulations of a Strong Pain Killer Release the Same Amount of Drug Into the Body as the Marketed Medication
To determine whether two new oral formulations of a strong pain killer release the drug into the body in a similar pattern as the already marketed reference capsule formulation with or without food.
- Trial name
- NCT02089581
- Testing
- Active comparator MR2XXX, MRXXX, MR1XXX
- Where
- 2 sites in United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Mundipharma Research Limited
Prostatic Hyperplasia
Comparative Bioavailability of Two Fixed Dose Combination (FDC) Formulations of Dutasteride and Tamsulosin Hydrochloride Relative to Co-administration of Dutasteride With Tamsulosin Hydrochloride in Healthy Male Subjects Under Fed and Fasted States
This study will be an open-label, randomized, single dose, three way crossover study in healthy male subjects. The aim of the study is to evaluate the pharmacokinetic parameters of two formulations of a fixed dose combination…
- Trial name
- NCT02184585
- Testing
- Treatment sequence A, Treatment sequence B, Treatment sequence C
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Opioid Substitution Treatment
Study to Assess Pharmacokinetic (PK), Bioavailability & Food Effect of MR902 Compared With Immediate Release (IR) Morphine Sulphate Oral Solution
A study to assess bioavailability of a single dose of MR902 and to assess the effect of food on absorption
- Trial name
- NCT02773316
- Testing
- MR902, IR morphine sulphate
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Mundipharma Research Limited
Health, Subjective, Food-drug Interaction
ABSK091 Food Effect Study in Healthy Subjects
In this study, a single oral dose of the tablet formulation administered under fed conditions will be compared to administration under fasted conditions to assess the effects of a high-fat meal on the rate and extent of…
- Trial name
- NCT05533788
- Testing
- ABSK091 tablet
- Where
- Taiwan
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Abbisko Therapeutics Co, Ltd
Chronic Kidney Disease
Study to Assess Relative Bioavailability and Safety of AZD5718 in Healthy Volunteers
This study will be a randomised, open-label, 3-period, 3-treatment, single-dose, crossover study in healthy subjects The study will be performed at a single study centre in the United Kingdom.
- Trial name
- NCT04734275
- Testing
- AZD5718
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers
Food Effect Study Of AG-013736 In Healthy Volunteers
The study is designed to evaluate the effect of food on typical blood levels obtained after oral dosing of AG-013736. Drug levels in blood will be compared after an overnight fast and a high-fat, high-calorie meal.
- Trial name
- NCT00918632
- Testing
- AG-013736
- Where
- Belgium
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study Comparing PF-06273340 Immediate Release Tablet, PF-06273340 Modified Release Tablets To PF-06273340 Oral Solution In The Fasted State. This Study Will Also Compare PF-06273340 Modified Release Tablets In Fasted And Fed State
The primary purpose of this study is to estimate the relative bioavailability and food effect of PF-06273340 tablets.
- Trial name
- NCT01706796
- Testing
- PF-06273340
- Where
- Singapore
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pain
Relative Bioavailability and Food Effect Study
Initial studies have used a powder in capsule formulation of PH797804. In future studies an immediate release tablet will be used.
- Trial name
- NCT00827515
- Testing
- PH797804
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Bioavailability
Bioavailability of Belumosudil (KD025) in Healthy Male Subjects
Phase 1 bioavailability study to evaluate the pharmacokinetics (PK) and tolerability/safety of the belumosudil tablet formulation in the fasted and fed states and compared to the belumosudil capsule formulation in the fed state.
- Trial name
- NCT02557139
- Testing
- Belumosudil Tablet, Belumosudil Capsule
- Where
- United Kingdom
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Kadmon Corporation, LLC